Durvalumab Treatment Regimen Reduces Risk of Disease Progres

Compared to TACE alone, durvalumab plus TACE and bevacizumab reduced the risk of disease progression or death by 23%; however, further research is needed to assess OS.

Related Keywords

San Francisco , California , United States , American , Bruno Sangro , Susan Galbraith , Genentech , Astrazeneca , Liver Unit , Universidad De Navarra ,